$MDT
Medtronic plc Stock $mdt

$mdt Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000161310320000033 Filed on September 03, 2020

Income Statement

Concept	2020 Q3	2019 Q3
Revenue	$6.507B	$7.493B
YoY Change	-13.16%	1.48%
Cost Of Revenue	$2.478B	$2.366B
YoY Change	4.73%	7.35%
Gross Profit	$4.029B	$5.127B
YoY Change	-21.42%	-1.02%
Gross Profit Margin	61.92%	68.42%
Selling, General & Admin	$2.370B	$2.543B
YoY Change	-6.8%	-2.08%
% of Gross Profit	58.82%	49.6%
Research & Development	$621.0M	$587.0M
YoY Change	5.79%	0.34%
% of Gross Profit	15.41%	11.45%
Depreciation & Amortization	$669.0M	$657.0M
YoY Change	1.83%	-1.35%
% of Gross Profit	16.6%	12.81%
Operating Expenses	$3.317B	$3.130B
YoY Change	5.97%	-1.63%
Operating Profit	$712.0M	$1.485B
YoY Change	-52.05%	20.15%
Interest Expense	-$119.0M	$609.0M
YoY Change	-119.54%	151.65%
% of Operating Profit	-16.71%	41.01%
Other Income/Expense, Net	$30.00M	$101.0M
YoY Change	-70.3%	-45.7%
Pretax Income	$584.0M	$977.0M
YoY Change	-40.23%	-17.2%
Income Tax	$93.00M	$100.0M
% Of Pretax Income	15.92%	10.24%
Net Earnings	$487.0M	$864.0M
YoY Change	-43.63%	-19.63%
Net Earnings / Revenue	7.48%	11.53%
Basic Earnings Per Share		$0.64
Diluted Earnings Per Share	$360.7K	$0.64
COMMON SHARES
Basic Shares Outstanding	1.344B shares	1.341B shares
Diluted Shares Outstanding		1.352B shares

Balance Sheet

Concept	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.01B	$10.68B
YoY Change	21.8%	-2.92%
Cash & Equivalents	$6.499B	$5.080B
Short-Term Investments	$6.513B	$5.603B
Other Short-Term Assets	$2.070B	$2.196B
YoY Change	-5.74%	4.52%
Inventory	$4.551B	$3.932B
Prepaid Expenses
Receivables	$4.876B	$5.894B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$24.51B	$22.71B
YoY Change	7.95%	1.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.882B	$4.711B
YoY Change	3.63%	4.13%
Goodwill	$40.71B	$40.08B
YoY Change	1.58%	2.89%
Intangibles	$18.67B	$20.23B
YoY Change	-7.73%	-4.87%
Long-Term Investments	$570.0M	$372.0M
YoY Change	53.23%	-25.6%
Other Assets	$2.143B	$1.991B
YoY Change	7.63%	81.16%
Total Long-Term Assets	$69.40B	$68.56B
YoY Change	1.22%	1.94%
TOTAL ASSETS
Total Short-Term Assets	$24.51B	$22.71B
Total Long-Term Assets	$69.40B	$68.56B
Total Assets	$93.91B	$91.27B
YoY Change	2.89%	1.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.720B	$1.906B
YoY Change	-9.76%	6.54%
Accrued Expenses	$5.153B	$4.430B
YoY Change	16.32%	-6.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.823B	$1.458B
YoY Change	299.38%	-5.63%
Total Short-Term Liabilities	$13.09B	$8.518B
YoY Change	53.63%	-6.52%
LONG-TERM LIABILITIES
Long-Term Debt	$22.87B	$24.80B
YoY Change	-7.81%	4.76%
Other Long-Term Liabilities	$1.598B	$1.590B
YoY Change	0.5%	98.5%
Total Long-Term Liabilities	$1.598B	$1.590B
YoY Change	0.5%	98.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.09B	$8.518B
Total Long-Term Liabilities	$1.598B	$1.590B
Total Liabilities	$43.46B	$40.77B
YoY Change	6.6%	3.5%
SHAREHOLDERS EQUITY
Retained Earnings	$27.82B	$26.38B
YoY Change	5.46%	6.66%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.30B	$50.36B
YoY Change
Total Liabilities & Shareholders Equity	$93.91B	$91.27B
YoY Change	2.89%	1.72%

Cashflow Statement

Concept	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	$487.0M	$864.0M
YoY Change	-43.63%	-19.63%
Depreciation, Depletion And Amortization	$669.0M	$657.0M
YoY Change	1.83%	-1.35%
Cash From Operating Activities	$278.0M	$1.510B
YoY Change	-81.59%	-11.28%
INVESTING ACTIVITIES
Capital Expenditures	-$334.0M	$301.0M
YoY Change	-210.96%	3.44%
Acquisitions		$145.0M
YoY Change		39.42%
Other Investing Activities	$342.0M	$5.000M
YoY Change	6740.0%
Cash From Investing Activities	$8.000M	-$551.0M
YoY Change	-101.45%	-185.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$333.0M
YoY Change		-59.59%
Debt Paid & Issued, Net		$5.035B
YoY Change		41858.33%
Cash From Financing Activities	1.959B	-$274.0M
YoY Change	-814.96%	-82.58%
NET CHANGE
Cash From Operating Activities	278.0M	$1.510B
Cash From Investing Activities	8.000M	-$551.0M
Cash From Financing Activities	1.959B	-$274.0M
Net Change In Cash	2.245B	$687.0M
YoY Change	226.78%	-11.01%
FREE CASH FLOW
Cash From Operating Activities	$278.0M	$1.510B
Capital Expenditures	-$334.0M	$301.0M
Free Cash Flow	$612.0M	$1.209B
YoY Change	-49.38%	-14.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	Medtronic plc
	dei	Entity Central Index Key EntityCentralIndexKey	0001613103
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 XH02
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201602Member
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-07-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36820
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1183488
	dei	Entity Address Address Line1 EntityAddressAddressLine1	20 On Hatch, Lower Hatch Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2
	dei	Entity Address Country EntityAddressCountry	IE
	dei	Country Region CountryRegion	353
	dei	City Area Code CityAreaCode	1
	dei	Local Phone Number LocalPhoneNumber	438-1700
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1344215261	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6507000000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7493000000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2505000000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2366000000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	621000000	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	587000000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2417000000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2543000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	440000000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	440000000	USD
	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	53000000	USD
CY2019Q3	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	47000000	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	-88000000	USD
CY2019Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	47000000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	114000000	USD
CY2019Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	22000000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	673000000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1485000000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	82000000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	101000000	USD
	us-gaap	Interest Expense InterestExpense	171000000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	609000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	584000000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	977000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	93000000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000000	USD
	us-gaap	Profit Loss ProfitLoss	491000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	4000000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	487000000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	864000000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.36
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.64
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1341900000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1340800000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1350000000.0	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1351900000	shares
	us-gaap	Profit Loss ProfitLoss	491000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	125000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	56000000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1117000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	66000000	USD
	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	-1112000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	99000000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-3000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-13000000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-350000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-7000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-217000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	227000000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	274000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1104000000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	9000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	13000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	265000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1091000000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6499000000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4140000000	USD
CY2020Q3	us-gaap	Short Term Investments ShortTermInvestments	6513000000	USD
CY2020Q2	us-gaap	Short Term Investments ShortTermInvestments	6808000000	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	276000000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	208000000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4876000000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4645000000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	4551000000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	4229000000	USD
CY2020Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2070000000	USD
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2209000000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	24509000000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	22031000000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11952000000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11644000000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7070000000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6816000000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4882000000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4828000000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	40714000000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	39841000000	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18670000000	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19063000000	USD
CY2020Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2988000000	USD
CY2020Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2832000000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2143000000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2094000000	USD
CY2020Q3	us-gaap	Assets Assets	93906000000	USD
CY2020Q2	us-gaap	Assets Assets	90689000000	USD
CY2020Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5823000000	USD
CY2020Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2776000000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1720000000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1996000000	USD
CY2020Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1815000000	USD
CY2020Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2099000000	USD
CY2020Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	390000000	USD
CY2020Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	502000000	USD
CY2020Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3338000000	USD
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2993000000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13086000000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10366000000	USD
CY2020Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	22867000000	USD
CY2020Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	22021000000	USD
CY2020Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1962000000	USD
CY2020Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1910000000	USD
CY2020Q3	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2719000000	USD
CY2020Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2682000000	USD
CY2020Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1231000000	USD
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2600000000	shares
CY2020Q3	us-gaap	Liabilities Liabilities	43463000000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	39817000000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1174000000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1598000000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1664000000	USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2600000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1343318623	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1343318623	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1341074724	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1341074724	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26261000000	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26165000000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	27817000000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	28132000000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3782000000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3560000000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	50296000000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	50737000000	USD
CY2020Q3	us-gaap	Minority Interest MinorityInterest	147000000	USD
CY2020Q2	us-gaap	Minority Interest MinorityInterest	135000000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50443000000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50872000000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93906000000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90689000000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50872000000	USD
	us-gaap	Profit Loss ProfitLoss	491000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-217000000	USD
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.58
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	778000000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	26000000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	70000000	USD
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	3000000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50443000000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50212000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	227000000	USD
CY2019Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.54
CY2019Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	724000000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	205000000	USD
CY2019Q3	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	328000000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	61000000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50497000000	USD
	us-gaap	Profit Loss ProfitLoss	491000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	669000000	USD
CY2019Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	657000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	37000000	USD
CY2019Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25000000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	3000000	USD
CY2019Q3	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	18000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	70000000	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	61000000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-406000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-68000000	USD
CY2019Q3	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-58000000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	142000000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-319000000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	235000000	USD
CY2019Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	122000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-541000000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-629000000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	142000000	USD
CY2019Q3	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	160000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	278000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1510000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2019Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	145000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	334000000	USD
CY2019Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	301000000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2045000000	USD
CY2019Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1669000000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2403000000	USD
CY2019Q3	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1569000000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	16000000	USD
CY2019Q3	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-551000000	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-16000000	USD
CY2019Q3	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	88000000	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	2789000000	USD
CY2019Q3	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2019Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5567000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11000000	USD
CY2019Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5035000000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	778000000	USD
CY2019Q3	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	724000000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	26000000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	210000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	333000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-51000000	USD
CY2019Q3	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-47000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1959000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-274000000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114000000	USD
CY2019Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2000000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2359000000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	687000000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4140000000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4393000000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6499000000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5080000000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	72000000	USD
CY2019Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	198000000	USD
	us-gaap	Interest Paid Net InterestPaidNet	72000000	USD
CY2019Q3	us-gaap	Interest Paid Net InterestPaidNet	86000000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation <div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Covid-19 pandemic ("COVID-19" or the "pandemic") is having, and will likely continue to have, an adverse effect on our business, results of operations, financial condition, and cash flows, and its future impacts remain highly uncertain and unpredictable. The Company has considered the disruptions caused by COVID-19, including lower than forecasted sales and customer demand and macroeconomic factors, that may impact its estimates. The Company has assessed the potential impact of the pandemic on certain accounting matters including, but not limited to, the allowance for doubtful accounts, inventory reserves, return reserves, the valuation of goodwill, intangible assets, other long-lived assets, investments and contingent consideration, as of July 31, 2020 and through the date of this report. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended July 31, 2020, changes in the Company’s assessment about the length and severity of the pandemic, as well as other factors, could result in actual results differing from estimates. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. </span></div>The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 24, 2020. The Company’s fiscal years 2021, 2020, and 2019 will end or ended on April 30, 2021, April 24, 2020, and April 26, 2019, respectively. Fiscal year 2021 is a 53-week year, with the extra week occurring in the first fiscal month of the first quarter.
	us-gaap	Fiscal Period FiscalPeriod	The Company’s fiscal years 2021, 2020, and 2019 will end or ended on April 30, 2021, April 24, 2020, and April 26, 2019, respectively. Fiscal year 2021 is a 53-week year, with the extra week occurring in the first fiscal month of the first quarter.
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6507000000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7493000000	USD
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	317000000	USD
CY2020Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	303000000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	103000000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	98000000	USD
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1000000000.0	USD
	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	four years
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	297000000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	280000000	USD
	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustments Related To Previous Period BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod	132000000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	280000000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	222000000	USD
	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	0	USD
CY2019Q3	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	58000000	USD
	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	1000000	USD
CY2019Q3	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	14000000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-18000000	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3000000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	297000000	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	269000000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	6399000000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	221000000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	72000000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	6548000000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	6847000000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	135000000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	141000000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	6841000000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	168000000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5000000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	1274000000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	67000000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1453000000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	6000000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	4019000000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	135000000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2403000000	USD
CY2019Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1567000000	USD
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	5000000	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	4000000	USD
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	6000000	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	8000000	USD
CY2020Q2	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0	USD
CY2020Q3	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0	USD
CY2019Q3	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1764000000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	3049000000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1677000000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	58000000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	6548000000	USD
CY2020Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5823000000	USD
CY2020Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2776000000	USD
CY2020Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	14000000	USD
CY2020Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	15000000	USD
CY2020Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	45000000	USD
CY2020Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	45000000	USD
CY2020Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	99000000	USD
CY2020Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	104000000	USD
CY2020Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	22867000000	USD
CY2020Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	22021000000	USD
CY2020Q3	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	28900000000	USD
CY2020Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	25500000000	USD
CY2020Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	27100000000	USD
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	24500000000	USD
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-100000000	USD
CY2019Q3	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-1000000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	114000000	USD
CY2019Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	22000000	USD
CY2020Q3	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	-84000000	USD
CY2020Q2	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	266000000	USD
	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	-4000000	USD
	mdt	Unrealized Gain Losson Net Investment Hedges Accumulated Other Comprehensive Income Loss Netof Tax UnrealizedGainLossonNetInvestmentHedgesAccumulatedOtherComprehensiveIncomeLossNetofTax	-876000000	USD
CY2020	mdt	Unrealized Gain Losson Net Investment Hedges Accumulated Other Comprehensive Income Loss Netof Tax UnrealizedGainLossonNetInvestmentHedgesAccumulatedOtherComprehensiveIncomeLossNetofTax	236000000	USD
	mdt	Net Investment Hedge Gain Losstobe Reclassified Within Twelve Months NetInvestmentHedgeGainLosstobeReclassifiedWithinTwelveMonths	0	USD
	mdt	Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet	0	USD
CY2019Q3	mdt	Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet	0	USD
CY2020Q3	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	140000000	USD
CY2020Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	192000000	USD
CY2020Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	402000000	USD
CY2020Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	42000000	USD
CY2020Q3	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	140000000	USD
CY2020Q3	us-gaap	Derivative Asset Not Offset Policy Election Deduction DerivativeAssetNotOffsetPolicyElectionDeduction	86000000	USD
CY2020Q3	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	0	USD
CY2020Q3	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	54000000	USD
CY2020Q3	mdt	Derivative Asset Liability Fair Value Gross Asset Liability DerivativeAssetLiabilityFairValueGrossAssetLiability	-52000000	USD
CY2020Q3	mdt	Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction	0	USD
CY2020Q3	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	-6000000	USD
CY2020Q3	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	-46000000	USD
CY2020Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	402000000	USD
CY2020Q2	us-gaap	Derivative Asset Not Offset Policy Election Deduction DerivativeAssetNotOffsetPolicyElectionDeduction	17000000	USD
CY2020Q2	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	48000000	USD
CY2020Q2	us-gaap	Derivative Liability Not Offset Policy Election Deduction DerivativeLiabilityNotOffsetPolicyElectionDeduction	17000000	USD
CY2020Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	USD
CY2020Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	337000000	USD
CY2020Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	42000000	USD
CY2020Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	25000000	USD
CY2020Q2	mdt	Derivative Asset Liability Fair Value Gross Asset Liability DerivativeAssetLiabilityFairValueGrossAssetLiability	360000000	USD
CY2020Q2	mdt	Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction	0	USD
CY2020Q2	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	48000000	USD
CY2020Q2	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	312000000	USD
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3024000000	USD
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2874000000	USD
CY2020Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	653000000	USD
CY2020Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	608000000	USD
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	874000000	USD
CY2020Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	747000000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	4551000000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	4229000000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	39841000000	USD
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	3000000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	870000000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	40714000000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28408000000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10179000000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28244000000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9704000000	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	440000000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	440000000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1319000000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1718000000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1654000000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1624000000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1599000000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1587000000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.159
CY2019Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.102
	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	4000000	USD
	mdt	Tax Expense Benefit Associated With Sale Of Intellectual Property TaxExpenseBenefitAssociatedWithSaleOfIntellectualProperty	-3000000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1500000000	USD
	mdt	Deferred Tax Assets Amortization Period DeferredTaxAssetsAmortizationPeriod	P20Y
	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	7000000	USD
CY2019Q3	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-30000000	USD
CY2019Q3	us-gaap	Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	-30000000	USD
CY2020Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1900000000	USD
CY2020Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1900000000	USD
CY2020Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	241000000	USD
CY2020Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1800000000	USD
CY2020Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	934000000	USD
CY2020Q2	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	911000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	487000000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	864000000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1341900000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1340800000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4700000	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	6900000	shares
	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	2700000	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3500000	shares
	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	700000	shares
CY2019Q3	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	700000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1350000000.0	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1351900000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.36
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.64
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70000000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	61000000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70000000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	61000000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	11000000	USD
CY2019Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	10000000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	59000000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	51000000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	Commitments and Contingencies <div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Legal Matters</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies litigation charges and gains related to significant legal matters as certain litigation charges. During the three months ended July 31, 2020, the Company recognized a net benefit of $88 million primarily related to favorable settlements for significant legal matters. During the three months ended July 26, 2019, the Company recognized $47 million of certain litigation charges. At July 31, 2020 and April 24, 2020, accrued litigation was approximately $0.4 billion and $0.5 billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">other accrued expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">other liabilities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Liability Matters</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Pelvic Mesh Litigation</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 16,200 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of August 5, 2020, the Company had reached agreements to settle approximately 15,900 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Hernia Mesh Litigation</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During fiscal year 2020, plaintiffs filed lawsuits against certain subsidiaries of the Company in U.S. state and federal courts alleging personal injury from hernia mesh products sold by those subsidiaries. The majority of the pending cases are in Massachusetts state court, where they have been consolidated before a single judge. Certain plaintiffs law firms have advised the Company that they may file additional cases in the future. The pending lawsuits relate to hernia mesh products that have not been subject to recalls, withdrawals or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Patent Litigation</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Ethicon</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed six of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Sasso</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is involved in litigation in Indiana relating to certain patent and royalty disputes with Dr. Sasso under agreements originally entered into in 1999 and 2001. On November 28, 2018, a jury in Indiana state court returned a verdict against the Company for approximately $112 million. The Company has strong arguments to appeal the verdict and has filed post-trial motions and appeals with the appropriate appellate courts. The Company's accrued expenses for this matter are included within accrued litigation as discussed above.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Shareholder Related Matters</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Covidien Acquisition</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Merenstein</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Steiner</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On March 20, 2015, the District Court issued an order and opinion granting Medtronic’s motion to dismiss the case. In May 2015, the plaintiffs filed an appeal, and, in January 2016, the Minnesota State Court of Appeals affirmed in part, and reversed in part. On April 19, 2016 the Minnesota Supreme Court granted the Company’s petition to review the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings, which are ongoing. In April 2020, the District Court issued an order and opinion denying the plaintiffs' motion for class certification. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Environmental Proceedings</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is a successor to a company that owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Following a trial in March 2002, the Court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the Court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The Court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. A third trial to determine the course of remediation to be pursued is scheduled to occur in fiscal year 2021.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Government Matters</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Since 2017, the Company has been responding to requests from the Department of Justice and U.S. Department of Health and Human Services for information about business practices relating to a neurovascular product developed and first marketed by ev3 and Covidien. The Company provided information in response to these requests and fully cooperated with the inquiry. The Department of Justice recently notified the Company that it does not intend to pursue the matter further. The Company has not recognized an expense in connection with this matter, because any such potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and on June 9, 2016, issued its opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal occurred on March 14, 2018. The 8th Circuit Court of Appeals issued their opinion on August 16, 2018, and remanded the case back to the U.S. Tax Court for additional factual findings. The U.S. Tax Court scheduled for April 2020 was postponed due to the challenges of COVID-19. The new trial date has not been re-scheduled.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2007 and 2008 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2009, 2010, and 2011 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2012. The statute of limitations for Covidien’s 2013 and 2014 U.S. federal income tax returns lapsed during the first quarter of fiscal years 2018 and 2019, respectively. Covidien's fiscal year 2015 U.S. federal income tax returns are currently being audited by the IRS. The statute of limitations for Covidien's 2016 U.S. federal income tax return lapsed during the third quarter of fiscal year 2020. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Refer to Note 11 for additional discussion of income taxes.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Guarantees</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Company’s sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, and/or cash flows.</span></div>
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	-88000000	USD
CY2019Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	47000000	USD
CY2020Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	400000000	USD
CY2020Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	500000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	584000000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	977000000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6507000000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7493000000	USD

Files In Submission

Name	View Source	Status
0001613103-20-000033-index-headers.html	Edgar Link	pending
0001613103-20-000033-index.html	Edgar Link	pending
0001613103-20-000033.txt	Edgar Link	pending
0001613103-20-000033-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mdt-20200731.htm	Edgar Link	pending
mdt-20200731.xsd	Edgar Link	pending
mdt-20200731_cal.xml	Edgar Link	unprocessable
mdt-20200731_def.xml	Edgar Link	unprocessable
mdt-20200731_g1.jpg	Edgar Link	pending
mdt-20200731_g2.jpg	Edgar Link	pending
mdt-20200731_g3.jpg	Edgar Link	pending
mdt-20200731_g4.jpg	Edgar Link	pending
mdt-20200731_g5.jpg	Edgar Link	pending
mdt-20200731_g6.jpg	Edgar Link	pending
mdt-20200731_g7.jpg	Edgar Link	pending
mdt-20200731_g8.jpg	Edgar Link	pending
mdt-20200731_htm.xml	Edgar Link	completed
mdt-20200731_lab.xml	Edgar Link	unprocessable
mdt-20200731_pre.xml	Edgar Link	unprocessable
mdt-2021q110qxex311.htm	Edgar Link	pending
mdt-2021q110qxex312.htm	Edgar Link	pending
mdt-2021q110qxex321.htm	Edgar Link	pending
mdt-2021q110qxex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDT
Medtronic plc Stock $mdt

2020 Q3 Form 10-Q Financial Statement

#000161310320000033 Filed on September 03, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT Medtronic plc Stock $mdt

2020 Q3 Form 10-Q Financial Statement

#000161310320000033 Filed on September 03, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT
Medtronic plc Stock $mdt